GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (LTS:0A4C) » Definitions » Short Percentage of Float

Altimmune (LTS:0A4C) Short Percentage of Float


View and export this data going back to 2020. Start your Free Trial

What is Altimmune Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Altimmune's Short Percentage of Float

For the Biotechnology subindustry, Altimmune's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Altimmune's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Altimmune's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Altimmune's Short Percentage of Float falls into.


Altimmune (LTS:0A4C) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (LTS:0A4C) » Definitions » Short Percentage of Float
Comparable Companies
HRTX OABI ALLO CABA TRDA LXEO NWBO ADPT OLMA YMAB OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
ALT:USA ALT1:Mexico 3G0:Germany
Address
910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878
Website
https://www.altimmune.com
Altimmune Inc is engaged on developing treatments for obesity and liver diseases. The Company's pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Altimmune (LTS:0A4C) Headlines

No Headlines